Aurinia licenses novel peptide AUR300 from Riptide for autoimmune/fibrotic diseases; $6M upfront

Aurinia Pharmaceuticals Inc.

Global licensing/research pact with Riptide for peptide AUR300 targeting M2 macrophages via CD206 receptor.
Aurinia pays $6M upfront; potential milestones and royalties on future sales of AUR300.
AUR300 reduces M2 dysregulation and inflammatory cytokines, aiming to treat autoimmune and fibrotic diseases.
Joint development committee formed; Riptide handles tech transfer and indication research activities.
Deal expands Aurinia's pipeline beyond LUPKYNIS into fibrosis and other autoimmune conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.